Xenobiotic metabolizing enzyme gene polymorphisms predict response to lung volume reduction surgery

Respiratory Research

Table 4 Analysis of SNPs in EPHX1 in all lung volume reduction surgery subjects (significant at p < 0.05) and in 4 subgroups defined by NETT based on upper lobe predominant emphysema on chest CT (upper lobe predominant vs. non-upper lobe predominant) and baseline exercise capacity (low vs. high). Subgroups with p-value <0.1 are shown

SNP	LVRS Response Phenotype	All subjects (n = 203)		Upper lobe, low exercise (n = 59)		Upper lobe, high exercise (n = 84)		Non-upper lobe, low exercise (n = 23)		Non-upper lobe, high exercise (n = 37)
		β	p	β	p	β	p	β	p	β	p
rs3753658	BODE	-0.8	0.008	-1.3	0.01
	UCSD SOBQ	-7.7	0.02	-11.7	0.05
rs1877724	Post-BD FEV₁, liters	-0.06	0.04	-0.13	0.01
rs2234922	BODE	0.5	0.02					1.6	0.02
	Max work, watts	-3.7	0.05
rs1051741	Max work, watts	-5.9	0.01					-8.4	0.09	-10.2	0.09
rs2292558	Max work, watts	-5.1	0.03					-8.4	0.09	-10.2	0.09

SNP = single nucleotide polymorphism; LVRS = lung volume reduction surgery; BODE = Body mass index, airflow Obstruction, Dyspnea, Exercise tolerance; BD = bronchodilator; FEV₁ = forced expiratory volume in 1 second; UCSD SOBQ = University of California, San Diego shortness of breath questionnaire (higher scores indicate more severe dyspnea)

ISSN: 1465-993X